These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 15664832)

  • 1. Pharmacophore identification of alpha(1A)-adrenoceptor antagonists.
    Li MY; Tsai KC; Xia L
    Bioorg Med Chem Lett; 2005 Feb; 15(3):657-64. PubMed ID: 15664832
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selective pharmacophore design for alpha1-adrenoceptor subtypes.
    MacDougall IJ; Griffith R
    J Mol Graph Model; 2006 Sep; 25(1):146-57. PubMed ID: 16406718
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ligand-based pharmacophore model of N-Aryl and N-Heteroaryl piperazine alpha 1A-adrenoceptors antagonists using GALAHAD.
    Zhao X; Yuan M; Huang B; Ji H; Zhu L
    J Mol Graph Model; 2010 Sep; 29(2):126-36. PubMed ID: 20538497
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Non-peptide angiotensin II receptor antagonists: chemical feature based pharmacophore identification.
    Krovat EM; Langer T
    J Med Chem; 2003 Feb; 46(5):716-26. PubMed ID: 12593652
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A specific pharmacophore model of Aurora B kinase inhibitors and virtual screening studies based on it.
    Wang HY; Li LL; Cao ZX; Luo SD; Wei YQ; Yang SY
    Chem Biol Drug Des; 2009 Jan; 73(1):115-26. PubMed ID: 19152640
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacophore identification of Raf-1 kinase inhibitors.
    Zhu T; Jiao Y; Chen YD; Wang X; Li HF; Zhang LY; Lu T
    Bioorg Med Chem Lett; 2008 Apr; 18(7):2346-50. PubMed ID: 18346893
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Farnesyltransferase pharmacophore model derived from diverse classes of inhibitors.
    Lu A; Zhang J; Yin X; Luo X; Jiang H
    Bioorg Med Chem Lett; 2007 Jan; 17(1):243-9. PubMed ID: 17049856
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacophore modeling and virtual screening for designing potential PLK1 inhibitors.
    Wang HY; Cao ZX; Li LL; Jiang PD; Zhao YL; Luo SD; Yang L; Wei YQ; Yang SY
    Bioorg Med Chem Lett; 2008 Sep; 18(18):4972-7. PubMed ID: 18762425
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The first pharmacophore model for potent NF-kappaB inhibitors.
    Tsai KC; Teng LW; Shao YM; Chen YC; Lee YC; Li M; Hsiao NW
    Bioorg Med Chem Lett; 2009 Oct; 19(19):5665-9. PubMed ID: 19726185
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacophore modeling and virtual screening for designing potential 5-lipoxygenase inhibitors.
    Aparoy P; Kumar Reddy K; Kalangi SK; Chandramohan Reddy T; Reddanna P
    Bioorg Med Chem Lett; 2010 Feb; 20(3):1013-8. PubMed ID: 20045317
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacophore identification of KSP inhibitors.
    Liu F; You QD; Chen YD
    Bioorg Med Chem Lett; 2007 Feb; 17(3):722-6. PubMed ID: 17095225
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 3D-pharmacophore models for selective A2A and A2B adenosine receptor antagonists.
    Wei J; Wang S; Gao S; Dai X; Gao Q
    J Chem Inf Model; 2007; 47(2):613-25. PubMed ID: 17330954
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacophore-based design, synthesis, biological evaluation, and 3D-QSAR studies of aryl-piperazines as alpha(1)-adrenoceptor antagonists.
    Li MY; Fang H; Xia L
    Bioorg Med Chem Lett; 2005 Jul; 15(13):3216-9. PubMed ID: 15935663
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemical function based pharmacophore generation of endothelin-A selective receptor antagonists.
    Funk OF; Kettmann V; Drimal J; Langer T
    J Med Chem; 2004 May; 47(11):2750-60. PubMed ID: 15139753
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A common feature-based 3D-pharmacophore model generation and virtual screening: identification of potential PfDHFR inhibitors.
    Adane L; Bharatam PV; Sharma V
    J Enzyme Inhib Med Chem; 2010 Oct; 25(5):635-45. PubMed ID: 19995305
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 3D QSAR pharmacophore based virtual screening and molecular docking for identification of potential HSP90 inhibitors.
    Sakkiah S; Thangapandian S; John S; Kwon YJ; Lee KW
    Eur J Med Chem; 2010 Jun; 45(6):2132-40. PubMed ID: 20206418
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The discovery of novel vascular endothelial growth factor receptor tyrosine kinases inhibitors: pharmacophore modeling, virtual screening and docking studies.
    Yu H; Wang Z; Zhang L; Zhang J; Huang Q
    Chem Biol Drug Des; 2007 Mar; 69(3):204-11. PubMed ID: 17441906
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 3D-pharmacophore model for RXR(gamma) agonists.
    Dong A; Wei J; Gao Q
    Neurochem Int; 2009; 54(5-6):286-91. PubMed ID: 19121355
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacophore modeling studies of type I and type II kinase inhibitors of Tie2.
    Xie QQ; Xie HZ; Ren JX; Li LL; Yang SY
    J Mol Graph Model; 2009 Feb; 27(6):751-8. PubMed ID: 19138543
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemical function-based pharmacophore development for novel, selective kappa opioid receptor agonists.
    Singh N; Nolan TL; McCurdy CR
    J Mol Graph Model; 2008 Sep; 27(2):131-9. PubMed ID: 18456526
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.